Can I read Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli on EtoBox?

Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli by Kayoko Hayakawa; Yasufumi Matsumura; Kohei Uemura; Shinya Tsuzuki; Aki Sakurai; Ryutaro Tanizaki; Koh Shinohara; Takehiro Hashimoto; Ryota Hase; Takashi Matono; Hideaki Kato; Momoko Mawatari; Hiroshi Hara; Yukihiro Hamada; Sho Saito; Norio Ohmagari; Yohei Doi is a Medicine article available to read on EtoBox.

What is Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli about?

## ABSTRACT Cefmetazole is active against extended-spectrum β-lactamase-producing __Escherichia coli__ (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and microbiological effectiveness, recurrence within 28 d, and all-cause mortality (14 d, 30 d, in-hospital). Outcomes were adjusted for the inverse probability of propensity scores for receiving cefmetazole or meropenem. Eighty-one and forty-six patients were included in the cefmetazole and meropenem groups, respectively. Bacteremia accounted for 43% of the cefmetazole group, and 59% of the meropenem group. The crude clinical effectiveness, 14 d, 30 d, and in-hospital mortality for patients in the cefmetazole and meropenem groups were 96.1% vs 90.9%, 0% vs 2.3%, 0% vs 12.5%, and 2.6% vs 13.3%, respectively. After propensity score adjustment, clinical effectivene

Who reads Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli?

Author

Kayoko Hayakawa; Yasufumi Matsumura; Kohei Uemura; Shinya Tsuzuki; Aki Sakurai; Ryutaro Tanizaki; Koh Shinohara; Takehiro Hashimoto; Ryota Hase; Takashi Matono; Hideaki Kato; Momoko Mawatari; Hiroshi Hara; Yukihiro Hamada; Sho Saito; Norio Ohmagari; Yohei Doi

Publisher

American Society for Microbiology

Published

2023

Field

Medicine (Health Sciences)